INNOGENE Co., Ltd.

As of June 30, 2026, INNOGENE Co., Ltd. carries a market capitalization of 15.52B, placing it among publicly traded companies globally. Its enterprise value stands at 8.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, INNOGENE Co., Ltd. has 10.94M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.32, and the price-to-book ratio stands at 1.29.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.44B versus a market cap of 15.52B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, INNOGENE Co., Ltd. maintains a current ratio of 9.05, meaning it holds 9.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.07, indicating moderate leverage, while an interest coverage ratio of -90.18 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, INNOGENE Co., Ltd. posted a negative return on equity (ROE) of -2.34, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.16, reflecting losses generated across the asset base. The company generates approximately 204.94M in revenue per employee across its workforce of 58.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.41 indicates how many times INNOGENE Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, INNOGENE Co., Ltd. recorded an income tax benefit of -4.61M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -317.28M and -312.67M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, INNOGENE Co., Ltd.'s stock has declined approximately 8.32% over the past 52 weeks. The 50-day moving average sits at 1,379.48, while the 200-day moving average is 1,487.52.

Over the twelve months ended June 30, 2026, INNOGENE Co., Ltd. generated 11.94B in revenue and converted that into -312.67M in net income, yielding earnings per share of -28.23. EBITDA reached -387.40M, while operating income came in at -641.19M.

As of June 30, 2026, INNOGENE Co., Ltd. holds 7.20B in cash and equivalents against 128.96M in total debt, resulting in a net debt position of -2.46B. Total book value stands at 12.05B, with working capital of 10.12B providing operational flexibility.

INNOGENE Co., Ltd. produced -967.26M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -348.53M in capital expenditures, free cash flow totaled -1.32B - equivalent to -118.79 per share.

Over the twelve months ended June 30, 2026, INNOGENE Co., Ltd. posted a gross margin of 52.45, reflecting its pricing power and cost economics. The operating margin of -5.37 and net profit margin of -2.62 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, INNOGENE Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -8.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 15.82, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to INNOGENE Co., Ltd. shareholders.

INNOGENE Co., Ltd.'s most recent stock split took place on April 29, 2022 with a 1:5 split ratio.

As of June 30, 2026, INNOGENE Co., Ltd. has an Altman Z-Score of 10.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.